250 related articles for article (PubMed ID: 11332679)
1. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
Kuyucu N; Kara C; Bakirtaç A; Teziç T
Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
[TBL] [Abstract][Full Text] [Related]
2. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C
Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769
[No Abstract] [Full Text] [Related]
3. Meglumine antimoniate-induced pancreatitis.
Torrús D; Massa B; Boix V; Portilla J; Pérez-Mateo M
Am J Gastroenterol; 1996 Apr; 91(4):820-1. PubMed ID: 8677970
[No Abstract] [Full Text] [Related]
4. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate-cure with ketoconazole and allopurinol.
Hueso M; Bover J; Serón D; Gil-Vernet S; Rufí G; Alsina J; Grinyó JM
Nephrol Dial Transplant; 1999 Dec; 14(12):2941-3. PubMed ID: 10570102
[No Abstract] [Full Text] [Related]
5. Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis.
Lambertucci JR; França BM; Queiroz Ede M
Rev Soc Bras Med Trop; 2004; 37(1):74-5. PubMed ID: 15042193
[No Abstract] [Full Text] [Related]
6. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy.
di Martino L; Mantovani MP; Gradoni L; Gramiccia M; Guandalini S
Trans R Soc Trop Med Hyg; 1990; 84(4):534-5. PubMed ID: 2091347
[No Abstract] [Full Text] [Related]
7. [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)].
Barthet M; Brunet P; Bernard JC; Dussol B; Rodor F; Jouglard J; Berland Y; Sahel J
Gastroenterol Clin Biol; 1994; 18(1):90-2. PubMed ID: 8187998
[No Abstract] [Full Text] [Related]
8. Severe leucopenia during treatment of visceral leishmaniasis.
Hiçsönmez G; Jama H; Ozsoylu S
Trans R Soc Trop Med Hyg; 1988; 82(3):417. PubMed ID: 3232176
[No Abstract] [Full Text] [Related]
9. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
[TBL] [Abstract][Full Text] [Related]
10. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
11. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV.
Laguna F; López-Vélez R; Soriano V; Montilla P; Alvar J; González-Lahoz JM
J Infect; 1994 May; 28(3):255-9. PubMed ID: 8089514
[TBL] [Abstract][Full Text] [Related]
12. Pentavalent antimonial-induced torsade de pointes.
Ortega-Carnicer J; Alcázar R; De la Torre M; Benezet J
J Electrocardiol; 1997 Apr; 30(2):143-5. PubMed ID: 9141610
[TBL] [Abstract][Full Text] [Related]
13. [Pancreatitis during treatment of leishmaniasis with n-methylglucamine antimoniate in a subject infected with HIV].
Trinchieri V; Ferone U; Monacelli M; Isceri L; Proietti F; Sorice F
Riv Eur Sci Med Farmacol; 1996; 18(2):49-51. PubMed ID: 9213843
[TBL] [Abstract][Full Text] [Related]
14. Pancreatitis associated with N-methyl-glucamine therapy in a dog with leishmaniasis.
Aste G; Di Tommaso M; Steiner JM; Williams DA; Boari A
Vet Res Commun; 2005 Aug; 29 Suppl 2():269-72. PubMed ID: 16244972
[No Abstract] [Full Text] [Related]
15. Chemotherapy of leishmaniasis in India.
Thakur CP
Indian J Pediatr; 1987; 54(1):7-10. PubMed ID: 3030933
[No Abstract] [Full Text] [Related]
16. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil.
Oliveira AL; Brustoloni YM; Fernandes TD; Dorval ME; Cunha RV; Bóia MN
Trop Doct; 2009 Jul; 39(3):180-2. PubMed ID: 19535762
[TBL] [Abstract][Full Text] [Related]
17. Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
Segura I; García-Bolao I
Resuscitation; 1999 Sep; 42(1):65-8. PubMed ID: 10524732
[TBL] [Abstract][Full Text] [Related]
18. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children.
Shahian M; Alborzi A
Med Sci Monit; 2009 Jun; 15(6):CR290-3. PubMed ID: 19478699
[TBL] [Abstract][Full Text] [Related]
19. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
[TBL] [Abstract][Full Text] [Related]
20. [N-methyl glucamine antimoniate or Glucantime].
Rapp C; Simon F; Dordain ML
Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
[No Abstract] [Full Text] [Related]
[Next] [New Search]
